KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other financing activities (2018 - 2025)

Sarepta Therapeutics has reported Other financing activities over the past 9 years, most recently at $110000.0 for Q4 2025.

  • Quarterly results put Other financing activities at $110000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $664000.0 (up 19.86% YoY), and the annual figure for FY2025 was $2.4 million, changed.
  • Other financing activities for Q4 2025 was $110000.0 at Sarepta Therapeutics, down from $554000.0 in the prior quarter.
  • Over the last five years, Other financing activities for SRPT hit a ceiling of $1.4 million in Q2 2021 and a floor of $110000.0 in Q4 2025.
  • Median Other financing activities over the past 3 years was $554000.0 (2022), compared with a mean of $698666.7.